Ben Hall

Ben Hall

Company: bluebird bio

Job title: Scientist, Analytical Development


Addressing Safety Assessment in Next Generation Products 11:30 am

• Autologous cellular therapies that incorporate gene editing require safety assays to ensure absence of aberrant transformation in final drug product • These assays include evaluating chromosomal abnormalities, IL-2 independent growth as a surrogate for malignant transformation, and changes resulting from on- or off-target editing • Challenges with these assays such as determining acceptance criteria,…Read more

day: Day 2 Track 1 AM

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.